Anzeige
Mehr »
Montag, 08.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12CNW | ISIN: SE0003883990 | Ticker-Symbol: 80R
Frankfurt
08.09.25 | 08:11
0,027 Euro
+3,88 % +0,001
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IDL DIAGNOSTICS AB Chart 1 Jahr
5-Tage-Chart
IDL DIAGNOSTICS AB 5-Tage-Chart
GlobeNewswire (Europe)
46 Leser
Artikel bewerten:
(0)

IDL Diagnostics AB: IDL Diagnostics AB (publ) Interim Report January 1st to June 30th, 2025

A word from the CEO
"In the second quarter, we have focused on creating a stable foundation to broaden and develop our sales, both in existing and upcoming new markets. A crucial factor for success is an attractive and relevant product range. The deepened cooperation with our partner Concile will play an important role in helping us achieve this goal.

Sales of our bladder cancer test, UBC Rapid, continued to show strong growth during the first half of the year with an increase of 18% compared with the same period last year. However, revenue for our typhoid fever test Tubex fell short of expectations, although it remains at a high level."

Anders Hultman, CEO

Reporting period April 1st - June 30th

  • Net sales amounted to KSEK 10,143 (15,273).
  • Profit after financial items amounted to KSEK -14,889 (-13,054)*.
  • Cash flow from operating activities for the period amounted to KSEK -1,798 (2,767).
  • Earnings per share before and after dilution amounted to SEK -0,06 (-0,06).
  • Cash and cash equivalents at the end of the period amounted to KSEK 44,265 (48,705).
  • EBITDA for the quarter amounted to KSEK -4,757 (-1,943).

*Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.

Reporting period January 1st - June 30th

  • Net sales amounted to KSEK 25,451 (28,076).
  • Profit after financial items amounted to KSEK -27,217 (-23,594)*.
  • Cash flow from operating activities for the period amounted to KSEK -2,910 (-1,447).
  • Earnings per share before and after dilution amounted to SEK -0,12 (-0,10).
  • Cash and cash equivalents at the end of the period amounted to KSEK 44,265 (48,705).
  • EBITDA for the period amounted to to KSEK -6,969 (-1,380).

* Includes costs for goodwill amortization of KSEK 19,789 (19,789) for the period.


Highlights

  • Deepened partnership
    IDL Diagnostics is expanding its collaboration with Concile. A letter of intent has been signed to strengthen the partnership and facilitate sales of concile's combined product portfolio outside Germany.
  • Focus on growth and business development
    Several initiatives have been undertaken to strengthen international presence. Among them by expanding our sales organization with a Sales Director, who will focus on new markets.
  • Company Name Change
    The company has changed its name from AroCell to IDL Diagnostics. The new name will serve as a unifying brand for all of the company's operations and products, while clarifying the company's direction and forming a strong foundation for continued growth.


Interim report January 1st - June 30th, 2025 (Link)

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com

This information is information that IDL Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-21 08:00 CEST.

© 2025 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.